154 related articles for article (PubMed ID: 16199990)
21. [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer].
Mizuta N; Nishiyama A; Mizuta M; Goto M; Imai A; Umeda Y; Morita M; Sakaguchi K; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1491-4. PubMed ID: 21918347
[TBL] [Abstract][Full Text] [Related]
22. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
Theodoulou M; Batist G; Campos S; Winer E; Welles L; Hudis C
Clin Breast Cancer; 2009 May; 9(2):101-7. PubMed ID: 19433391
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
[TBL] [Abstract][Full Text] [Related]
26. A feasibility study of neo-adjuvant low-dose fractionated radiotherapy with two different concurrent anthracycline-docetaxel schedules in stage IIA/B-IIIA breast cancer.
Nardone L; Valentini V; Marino L; De Santis MC; Terribile D; Franceschini G; Balducci M; Mantini G; Mattiucci G; Mulè A; Belli P; Masetti R
Tumori; 2012; 98(1):79-85. PubMed ID: 22495705
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
Horton JK; Halle J; Ferraro M; Carey L; Moore DT; Ollila D; Sartor CI
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):998-1004. PubMed ID: 19560883
[TBL] [Abstract][Full Text] [Related]
29. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Koukourakis MI; Romanidis K; Froudarakis M; Kyrgias G; Koukourakis GV; Retalis G; Bahlitzanakis N
Br J Cancer; 2002 Aug; 87(4):385-92. PubMed ID: 12177774
[TBL] [Abstract][Full Text] [Related]
30. Herceptin and chemotherapy combination active in advanced breast cancer.
Cancer Biol Ther; 2004 Jun; 3(6):489. PubMed ID: 15717405
[No Abstract] [Full Text] [Related]
31. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
32. Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer.
Okawa Y; Sugiyama K; Aiba K; Hirano A; Uno S; Hagino T; Kawase K; Shioya H; Yoshida K; Usui N; Kobayashi M; Kobayashi T
Breast Cancer; 2004; 11(3):309-12. PubMed ID: 15550852
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
[TBL] [Abstract][Full Text] [Related]
34. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
35. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
[TBL] [Abstract][Full Text] [Related]
37. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
Julka PK; Sharma DN; Mukhopadhyay P; Rath GK
Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):115-8. PubMed ID: 15074734
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer.
Sawaki M; Iwata H; Sato Y; Wada M; Toyama T; Sasaki E; Yatabe Y; Imai T; Ohashi Y
Breast; 2010 Oct; 19(5):370-6. PubMed ID: 20472435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
